Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Income from Continuing Operations (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Income from Continuing Operations for 16 consecutive years, with 630512.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 12.61% to 630512.0 in Q3 2025 year-over-year; TTM through Jul 2025 was 2871358.0, a 172.75% decrease, with the full-year FY2025 number at 2962301.0, down 185.4% from a year prior.
  • Income from Continuing Operations was 630512.0 for Q3 2025 at PharmaCyte Biotech, up from 812788.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6170980.0 in Q2 2024 to a low of 1879449.0 in Q4 2022.
  • A 5-year average of 561571.37 and a median of 812788.0 in 2025 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 3521.74% in 2024, then crashed 113.17% in 2025.
  • PharmaCyte Biotech's Income from Continuing Operations stood at 980837.0 in 2021, then tumbled by 91.62% to 1879449.0 in 2022, then surged by 72.58% to 515339.0 in 2023, then tumbled by 40.39% to 723498.0 in 2024, then grew by 12.85% to 630512.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Income from Continuing Operations are 630512.0 (Q3 2025), 812788.0 (Q2 2025), and 704560.0 (Q1 2025).